Published by Josh White on 16th August 2024
(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) has approved its drug durvalumab, branded Imfinzi, for the treatment of early-stage non-small cell lung cancer (NSCLC) in patients eligible for surgery.
URL: http://www.digitallook.com/dl/news/story/34497332/...